טוען...
Profile of infliximab in the treatment of pediatric Crohn’s disease
In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn’s disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the grow...
שמור ב:
| הוצא לאור ב: | Pediatric Health Med Ther |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5683274/ https://ncbi.nlm.nih.gov/pubmed/29388577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PHMT.S64943 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|